Compare ESLT & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLT | INSM |
|---|---|---|
| Founded | 1966 | 1988 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 35.2B |
| IPO Year | 2002 | 2000 |
| Metric | ESLT | INSM |
|---|---|---|
| Price | $766.80 | $149.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 23 |
| Target Price | ★ $550.33 | $188.73 |
| AVG Volume (30 Days) | 123.9K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.91 | $130.70 |
| Revenue Next Year | $9.55 | $74.05 |
| P/E Ratio | $71.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $328.32 | $60.40 |
| 52 Week High | $775.99 | $212.75 |
| Indicator | ESLT | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 69.66 | 41.80 |
| Support Level | $456.48 | $139.81 |
| Resistance Level | N/A | $167.01 |
| Average True Range (ATR) | 23.07 | 6.83 |
| MACD | 5.29 | 0.61 |
| Stochastic Oscillator | 92.87 | 27.83 |
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.